143 related articles for article (PubMed ID: 36590413)
1. Evaluation of analogs of mutacin 1140 in systemic and cutaneous methicillin-resistant
Ju M; Joseph T; Hansanant N; Geng M; Williams M; Cothrell A; Buhrow AR; Austin F; Smith L
Front Microbiol; 2022; 13():1067410. PubMed ID: 36590413
[TBL] [Abstract][Full Text] [Related]
2. Efficacious Analogs of the Lantibiotic Mutacin 1140 against a Systemic Methicillin-Resistant Staphylococcus aureus Infection.
Geng M; Ravichandran A; Escano J; Smith L
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275083
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic activity of the lantibiotic MU1140.
Ghobrial OG; Derendorf H; Hillman JD
Int J Antimicrob Agents; 2009 Jan; 33(1):70-4. PubMed ID: 18835136
[TBL] [Abstract][Full Text] [Related]
4. Carboxyl Analogue of Mutacin 1140, a Scaffold for Lead Antibacterial Discovery.
Escano J; Ravichandran A; Salamat B; Smith L
Appl Environ Microbiol; 2017 Jul; 83(14):. PubMed ID: 28500042
[TBL] [Abstract][Full Text] [Related]
5. Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and Stability.
Geng M; Smith L
Appl Environ Microbiol; 2018 Aug; 84(15):. PubMed ID: 29776930
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of pore formation and membrane disruption by the antimicrobial lantibiotic peptide Mutacin 1140.
Pokhrel R; Bhattarai N; Baral P; Gerstman BS; Park JH; Handfield M; Chapagain PP
Phys Chem Chem Phys; 2019 Jun; 21(23):12530-12539. PubMed ID: 31147666
[TBL] [Abstract][Full Text] [Related]
7. Mutacin 1140 Lantibiotic Variants Are Efficacious Against
Kers JA; Sharp RE; Defusco AW; Park JH; Xu J; Pulse ME; Weiss WJ; Handfield M
Front Microbiol; 2018; 9():415. PubMed ID: 29615987
[TBL] [Abstract][Full Text] [Related]
8. Complete synthesis of the bicyclic ring of a mutacin analog with orthogonally protected lanthionine via solid-phase intracyclization.
Kirichenko K; Hillman JD; Handfield M; Park JH
J Pept Sci; 2019 Nov; 25(11):e3214. PubMed ID: 31721375
[TBL] [Abstract][Full Text] [Related]
9. The Novel Oxazolidinone TBI-223 Is Effective in Three Preclinical Mouse Models of Methicillin-Resistant Staphylococcus aureus Infection.
Gordon O; Dikeman DA; Ortines RV; Wang Y; Youn C; Mumtaz M; Orlando N; Zhang J; Patel AM; Gough E; Kaushik A; Nuermberger EL; Upton AM; Fotouhi N; Miller LS; Archer NK
Microbiol Spectr; 2022 Oct; 10(5):e0245121. PubMed ID: 36106881
[TBL] [Abstract][Full Text] [Related]
10. The Killing Mechanism of Teixobactin against Methicillin-Resistant Staphylococcus aureus: an Untargeted Metabolomics Study.
Hussein M; Karas JA; Schneider-Futschik EK; Chen F; Swarbrick J; Paulin OKA; Hoyer D; Baker M; Zhu Y; Li J; Velkov T
mSystems; 2020 May; 5(3):. PubMed ID: 32457238
[TBL] [Abstract][Full Text] [Related]
11. A 3-alkylpyridine-bearing alkaloid exhibits potent antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA) with no detectable resistance.
Herrera KMS; Lopes GFM; Oliveira ME; Sousa JF; Lima WG; Silva FK; Brito JCM; Gomes AJPS; Viana GHR; Soares AC; Ferreira JMS
Microbiol Res; 2022 Aug; 261():127073. PubMed ID: 35636092
[TBL] [Abstract][Full Text] [Related]
12. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
13. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia.
Roghmann MC
Arch Intern Med; 2000 Apr; 160(7):1001-4. PubMed ID: 10761966
[TBL] [Abstract][Full Text] [Related]
14. Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140.
Ghobrial O; Derendorf H; Hillman JD
Eur J Pharm Sci; 2010 Dec; 41(5):658-64. PubMed ID: 20869439
[TBL] [Abstract][Full Text] [Related]
15. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Stein GE; Wells EM
Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous community-acquired methicillin-resistant Staphylococcus aureus infection in participants of athletic activities.
Cohen PR
South Med J; 2005 Jun; 98(6):596-602. PubMed ID: 16004165
[TBL] [Abstract][Full Text] [Related]
17. [The history of the development and changes of quinolone antibacterial agents].
Takahashi H; Hayakawa I; Akimoto T
Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
[TBL] [Abstract][Full Text] [Related]
18. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
19. Marinopyrrole derivatives as potential antibiotic agents against methicillin-resistant Staphylococcus aureus (II).
Cheng C; Liu Y; Song H; Pan L; Li J; Qin Y; Li R
Mar Drugs; 2013 Aug; 11(8):2927-48. PubMed ID: 23955285
[TBL] [Abstract][Full Text] [Related]
20. A Strong Synergy Between the Thiopeptide Bacteriocin Micrococcin P1 and Rifampicin Against MRSA in a Murine Skin Infection Model.
Ovchinnikov KV; Kranjec C; Telke A; Kjos M; Thorstensen T; Scherer S; Carlsen H; Diep DB
Front Immunol; 2021; 12():676534. PubMed ID: 34276663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
